BYSI Quote, Financials, Valuation and Earnings

KalVista Pharmaceuticals, Inc. has a net margin of -- compared to BeyondSpring, Inc.'s net margin of -361.39%. BeyondSpring, Inc.'s return on equity of -- beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

BeyondSpring, Inc. has a consensus price target of --, signalling downside risk potential of -34.21%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 111.46%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than BeyondSpring, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than BeyondSpring, Inc..

BeyondSpring, Inc. has a beta of 0.528, which suggesting that the stock is 47.227% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

BeyondSpring, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BeyondSpring, Inc. quarterly revenues are --, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. BeyondSpring, Inc.'s net income of -$1.7M is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, BeyondSpring, Inc.'s price-to-earnings ratio is 25.86x while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring, Inc. is 29.97x versus 50.86x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solid Biosciences, Inc. has a net margin of -- compared to BeyondSpring, Inc.'s net margin of --. BeyondSpring, Inc.'s return on equity of -- beat Solid Biosciences, Inc.'s return on equity of -77.74%.

BeyondSpring, Inc. has a consensus price target of --, signalling downside risk potential of -34.21%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.17 which suggests that it could grow by 192.23%. Given that Solid Biosciences, Inc. has higher upside potential than BeyondSpring, Inc., analysts believe Solid Biosciences, Inc. is more attractive than BeyondSpring, Inc..

BeyondSpring, Inc. has a beta of 0.528, which suggesting that the stock is 47.227% less volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.975, suggesting its more volatile than the S&P 500 by 197.54%.

BeyondSpring, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring, Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.

BeyondSpring, Inc. quarterly revenues are --, which are smaller than Solid Biosciences, Inc. quarterly revenues of --. BeyondSpring, Inc.'s net income of -$1.7M is higher than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, BeyondSpring, Inc.'s price-to-earnings ratio is 25.86x while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring, Inc. is 29.97x versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -- compared to BeyondSpring, Inc.'s net margin of 15.59%. BeyondSpring, Inc.'s return on equity of -- beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

BeyondSpring, Inc. has a consensus price target of --, signalling downside risk potential of -34.21%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Travere Therapeutics, Inc. has higher upside potential than BeyondSpring, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than BeyondSpring, Inc..

BeyondSpring, Inc. has a beta of 0.528, which suggesting that the stock is 47.227% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

BeyondSpring, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

BeyondSpring, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. BeyondSpring, Inc.'s net income of -$1.7M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, BeyondSpring, Inc.'s price-to-earnings ratio is 25.86x while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring, Inc. is 29.97x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -- compared to BeyondSpring, Inc.'s net margin of -49.65%. BeyondSpring, Inc.'s return on equity of -- beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

BeyondSpring, Inc. has a consensus price target of --, signalling downside risk potential of -34.21%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than BeyondSpring, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than BeyondSpring, Inc..

BeyondSpring, Inc. has a beta of 0.528, which suggesting that the stock is 47.227% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

BeyondSpring, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeyondSpring, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

BeyondSpring, Inc. quarterly revenues are --, which are smaller than Xenetic Biosciences, Inc. quarterly revenues of $1M. BeyondSpring, Inc.'s net income of -$1.7M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, BeyondSpring, Inc.'s price-to-earnings ratio is 25.86x while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeyondSpring, Inc. is 29.97x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.